- Home
- CLRB vs EEA Comparison
CLRB vs EEA Comparison
Compare CLRB & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- EEA
- Stock Information
- Founded
- CLRB 2002
- EEA 1986
- Country
- CLRB United States
- EEA Germany
- Employees
- CLRB N/A
- EEA N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- EEA Trusts Except Educational Religious and Charitable
- Sector
- CLRB Health Care
- EEA Finance
- Exchange
- CLRB Nasdaq
- EEA Nasdaq
- Market Cap
- CLRB 76.0M
- EEA 60.8M
- IPO Year
- CLRB N/A
- EEA N/A
- Fundamental
- Price
- CLRB $1.86
- EEA $8.50
- Analyst Decision
- CLRB Strong Buy
- EEA
- Analyst Count
- CLRB 2
- EEA 0
- Target Price
- CLRB $21.00
- EEA N/A
- AVG Volume (30 Days)
- CLRB 289.0K
- EEA 9.2K
- Earning Date
- CLRB 11-18-2024
- EEA 01-01-0001
- Dividend Yield
- CLRB N/A
- EEA 1.92%
- EPS Growth
- CLRB N/A
- EEA N/A
- EPS
- CLRB N/A
- EEA N/A
- Revenue
- CLRB N/A
- EEA N/A
- Revenue This Year
- CLRB N/A
- EEA N/A
- Revenue Next Year
- CLRB N/A
- EEA N/A
- P/E Ratio
- CLRB N/A
- EEA N/A
- Revenue Growth
- CLRB N/A
- EEA N/A
- 52 Week Low
- CLRB $1.82
- EEA $7.45
- 52 Week High
- CLRB $4.45
- EEA $9.26
- Technical
- Relative Strength Index (RSI)
- CLRB 30.70
- EEA 32.37
- Support Level
- CLRB $1.97
- EEA $8.71
- Resistance Level
- CLRB $2.18
- EEA $8.57
- Average True Range (ATR)
- CLRB 0.10
- EEA 0.16
- MACD
- CLRB -0.01
- EEA -0.03
- Stochastic Oscillator
- CLRB 8.11
- EEA 6.05
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.